Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, announces that the first patient has been enrolled in the investigator-initiated LEOPARD trial evaluating the potential of OCS-01 eye drops, Oculis’ novel high concentration preservative-free topical OPTIREACH formulation of dexamethasone, for the treatment of cystoid macular edema (CME).
CME may occur as a complication of ocular conditions, including uveitis and ocular surgery, and is a leading cause of vision loss worldwide. It is one of the most significant causes of postoperative vision loss after cataract surgery1. Approximately 28% of patients who undergo ocular surgery, including patients with diabetes, uveitis and other risk factors, have a higher risk of developing CME following the procedure2. Up to 56% of high-risk patients may experience clinically significant CME following ocular surgery1.
The LEOPARD trial, administratively sponsored by the Global Ophthalmic Research Center (Los Altos, California) and led by Quan Dong Nguyen, MD, MSc, FAAO, FARVO, FASRS, Professor of Ophthalmology at the Byers Eye Institute, Stanford University School of Medicine, aims to evaluate the efficacy and safety profile of OCS-01 eye drops in the management of two different forms of CME: Uveitic Macular Edema (UME) and Post-Surgical Macular Edema (PSME). It is a prospective, multi-center, open label, single-armed trial which plans on enrolling 24 eligible subjects (12 with UME and 12 with PSME). Two different doses will be used, and the total treatment period is 24 weeks. The primary endpoints, which will be assessed at 12 weeks, are improvement in central subfield thickness (CST) and visual acuity.
CME is being explored with OCS-01 eye drops, in addition to diabetic macular edema (DME) and inflammation and pain post ocular surgery, both indications currently in Phase 3 clinical development. OCS-01 has demonstrated its potential to reduce macular edema as measured by improvements in retinal thickness in a pilot study with uveitic macular edema patients as well as in the recently completed Stage 1 of the Phase 3 DIAMOND trial in patients with DME.
Professor Nguyen, who is a member of the Oculis Scientific Advisory Board, commented: “I am very excited to investigate the potential of OCS-01 eye drops for the treatment of cystoid macular edema, one of the most common causes of decreased vision in patients following cataract and other ophthalmic surgeries, and in uveitis patients. Given the recently announced DIAMOND Phase 3 Stage 1 data readout in DME, which showed statistically significant reduction in retinal thickness with OCS-01, we believe in its potential to provide a paradigm shift in the treatment of post-surgical and uveitic macular edema, in addition to DME.”
Riad Sherif, M.D., Chief Executive Officer of Oculis, concluded: “Oculis is proud to support this investigator-initiated trial led by Professor Nguyen in cystoid macular edema with OCS-01 eye drops, to explore its potential in this vision-threatening eye condition. OCS-01 is Oculis’ lead compound currently being investigated in two Phase 3 clinical trials in DME as well as inflammation and pain following with ocular surgery with promising efficacy and safety data.”